IP Library Granted Patent US 12,642,293
Granted Patent B2
US 12,642,293 · App. 18/203,082 · Granted Jun 2, 2026

Polysaccharide-based tobacco gel compositions

Inventors: Samira Bagheri (Mountain View, CA); Namhey Lee (Hayward, CA); Anusha Saripalli (Santa Clara, CA); Krishnamohan Sharma (Milpitas, CA)
Assignee: JUUL Labs, Inc.
A24B15/42A24B15/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,293
App. No.
18/203,082
Granted
Jun 2, 2026
Kind
B2
Abstract

Compositions include an aqueous polysaccharide-based gellant system including a polysaccharide and a gel modifier, and a tobacco material. Other compositions include a cellulose matrix, a tobacco material, and a water-soluble polymer. Still other compositions include an alginate, a tobacco material, and an alginate crosslinker. These compositions may be placed in a cartridge for use in a device for delivering nicotine to a user.

Claims (23)

1 . A composition comprising:

an aqueous polysaccharide-based gellant system comprising:

a polysaccharide; and

a gel modifier, wherein the gel modifier is a water-soluble polymer selected from the group consisting of a poloxamer, a polyether, a polyacrylamide, a polyoxazoline, a polyphosphate, an albumin, and combinations thereof; and

a tobacco material;

wherein the polysaccharide comprises a cellulose matrix, the tobacco material is disposed within the cellulose matrix, and the water-soluble polymer encapsulates the cellulose matrix.

2 . The composition of claim 1 , further comprising a hydrated ionic clay.

3 . The composition of claim 2 , wherein the hydrated ionic clay is between 1 wt % to 10 wt % of the composition.

4 . The composition of claim 3 , wherein the hydrated ionic clay is between 1 wt % to 4 wt % of the composition.

5 . The composition of claim 4 , wherein the hydrated ionic clay is between 1 wt % to 3 wt % of the composition.

6 . The composition of claim 5 , wherein the hydrated ionic clay is between 1 wt % to 2 wt % of the composition.

7 . The composition of claim 1 , wherein the tobacco material is between 5 wt % to 95 wt % of the composition.

8 . The composition of claim 7 , wherein the tobacco material is between 40 wt % to 90 wt % of the composition.

9 . The composition of claim 8 , wherein the tobacco material is between 40 wt % to 80 wt % of the composition.

10 . The composition of claim 9 , wherein the tobacco material is between 40 wt % to 60 wt % of the composition.

11 . The composition of claim 10 , wherein the tobacco material is between 40 wt % to 50 wt % of the composition.

12 . The composition of claim 7 , wherein the tobacco material is between 50 wt % to 90 wt % of the composition.

13 . The composition of claim 12 , wherein the tobacco material is between 50 wt % to 80 wt % of the composition.

14 . The composition of claim 13 , wherein the tobacco material is between 50 wt % to 70 wt % of the composition.

15 . The composition of claim 14 , wherein the tobacco material is between 50 wt % to 60 wt % of the composition.

16 . The composition of claim 7 , wherein the tobacco material is between 80 wt % to 95 wt % of the composition.

17 . The composition of claim 16 , wherein the tobacco material is between 90 wt % to 95 wt % of the composition.

18 . The composition of claim 1 , wherein water is present between 5 wt % to 90 wt % of the composition.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 17, 2024
From: ALTER DOMUS (US) LLC
To: JUUL LABS, INC.; VMR PRODUCTS LLC; ENVENIO INC.
Reel/Frame 069185/0228 →
SECURITY INTEREST Recorded Sep 5, 2023
From: JUUL LABS, INC.
To: JLI NATIONAL SETTLEMENT TRUST
Reel/Frame 064796/0755 →
SECURITY INTEREST Recorded Aug 2, 2023
From: JUUL LABS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 064476/0206 →
SECURITY INTEREST Recorded Jul 11, 2023
From: JUUL LABS, INC.; VMR PRODUCTS LLC; ENVENIO INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 064252/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: BAGHERI, SAMIRA; LEE, NAMHEY; SARIPALLI, ANUSHA; SHARMA, KRISHNAMOHAN
To: JUUL LABS, INC.
Reel/Frame 063790/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: BAGHERI, SAMIRA; LEE, NAMHEY; SARIPALLI, ANUSHA; SHARMA, KRISHNAMOHAN
To: JUUL LABS, INC.
Reel/Frame 063791/0604 →
Continuity (3)
Continuation PCTUS2021059899 · Nov 18, 2021
Provisional Application 63119486 · Nov 30, 2020
Related Publication 20230292814A1 · Sep 21, 2023
References Cited (115)
US 2162738A · McCoy · 1939 [cited by applicant]
US 2938818A · Specht · 1960 [cited by applicant]
US 3012915A · Howard · 1961 [cited by applicant]
US 3847326A · Webster · 1974 [cited by applicant]
US 3880172A · Anderson et al. · 1975 [cited by applicant]
US 4147172A · Calder et al. · 1979 [cited by applicant]
US 5525351A · Dam · 1996 [cited by applicant]
US 6344222B1 · Cherukuri et al. · 2002 [cited by applicant]
US 7040314B2 · Nguyen et al. · 2006 [cited by applicant]
US 7581540B2 · Hale et al. · 2009 [cited by applicant]
US 8356606B2 · Sengupta et al. · 2013 [cited by applicant]
US 8402978B2 · Karles et al. · 2013 [cited by applicant]
US 8485180B2 · Smutney et al. · 2013 [cited by applicant]
US 8741348B2 · Hansson et al. · 2014 [cited by applicant]
US 8893724B2 · Woodcock et al. · 2014 [cited by applicant]
US 10195345B2 · Senior et al. · 2019 [cited by applicant]
US 10328443B2 · Ricketts et al. · 2019 [cited by applicant]
US 10609958B2 · Robinson et al. · 2020 [cited by applicant]
US 10856573B2 · Pijnenburg et al. · 2020 [cited by applicant]
US 10952452B2 · Sengupta et al. · 2021 [cited by applicant]
US 11053395B2 · Karles et al. · 2021 [cited by applicant]
US 11246344B2 · Griffith, Jr. et al. · 2022 [cited by applicant]
US 11259569B2 · Hejazi · 2022 [cited by applicant]
US 20050056294A1 · Wanna et al. · 2005 [cited by applicant]
US 20060032501A1 · Hale · 2006 [cited by examiner]
US 20060171990A1 · Asgari · 2006 [cited by applicant]
US 20060191548A1 · Strickland et al. · 2006 [cited by applicant]
US 20100006092A1 · Hale et al. · 2010 [cited by applicant]
US 20110083681A1 · Sengupta et al. · 2011 [cited by applicant]
US 20110232657A1 · Karles et al. · 2011 [cited by applicant]
US 20120152264A1 · Coleman et al. · 2012 [cited by applicant]
US 20120199149A1 · Strickland et al. · 2012 [cited by applicant]
US 20130186418A1 · Gao · 2013 [cited by examiner]
US 20130255702A1 · Griffith, Jr. et al. · 2013 [cited by applicant]
US 20150013693A1 · Fuisz et al. · 2015 [cited by applicant]
US 20150068545A1 · Moldoveanu et al. · 2015 [cited by applicant]
US 20160136153A1 · Jenkins · 2016 [cited by applicant]
US 20160295910A1 · Besso et al. · 2016 [cited by applicant]
US 20170071249A1 · Ampolini et al. · 2017 [cited by applicant]
US 20170099877A1 · Worm et al. · 2017 [cited by applicant]
US 20170251714A1 · Mishra et al. · 2017 [cited by applicant]
US 20170265517A1 · Swede et al. · 2017 [cited by applicant]
US 20170340005A1 · Terao · 2017 [cited by applicant]
US 20180029782A1 · Zuber et al. · 2018 [cited by applicant]
US 20180042302A1 · Robinson et al. · 2018 [cited by applicant]
US 20180084823A1 · Fuisz et al. · 2018 [cited by applicant]
US 20180199617A1 · Iodice · 2018 [cited by applicant]
US 20180228203A1 · Pithawalla et al. · 2018 [cited by applicant]
US 20180310624A1 · Parker et al. · 2018 [cited by applicant]
US 20190183177A1 · Hubbard et al. · 2019 [cited by applicant]
US 20210177039A1 · Yao · 2021 [cited by examiner]
US 20210315257A1 · Aoun et al. · 2021 [cited by applicant]
US 20220211092A1 · Arafat Arafat · 2022 [cited by applicant]
US 20220312841A1 · Diokno et al. · 2022 [cited by applicant]
US 20240260654A1 · Ashraf · 2024 [cited by examiner]
CA 622523A · 1961 [cited by applicant]
CN 102316850A · 2012 [cited by applicant]
CN 108277085A · 2018 [cited by applicant]
CN 108366614A · 2018 [cited by applicant]
CN 109105944A · 2019 [cited by applicant]
CN 109310622A · 2019 [cited by applicant]
CN 111685388A · 2020 [cited by applicant]
EP 0135265A2 · 1985 [cited by applicant]
EP 0405190A2 · 1991 [cited by applicant]
EP 0509657A1 · 1992 [cited by applicant]
EP 0419974B1 · 1996 [cited by applicant]
EP 2077731B1 · 2011 [cited by applicant]
EP 2205105B1 · 2012 [cited by applicant]
EP 2645886B1 · 2015 [cited by applicant]
EP 2753197B1 · 2015 [cited by applicant]
EP 2552237B1 · 2016 [cited by applicant]
EP 2844088B1 · 2016 [cited by applicant]
EP 2741625B1 · 2017 [cited by applicant]
EP 2811849B1 · 2018 [cited by applicant]
EP 2552248B1 · 2019 [cited by applicant]
EP 2632562B1 · 2020 [cited by applicant]
EP 3089602B1 · 2020 [cited by applicant]
EP 3110264B1 · 2020 [cited by applicant]
EP 3481237B1 · 2020 [cited by applicant]
EP 3297460B1 · 2020 [cited by applicant]
EP 3110265B1 · 2021 [cited by applicant]
EP 3240442B1 · 2022 [cited by applicant]
EP 3240439B1 · 2022 [cited by applicant]
EP 3911390B1 · 2022 [cited by applicant]
EP 3846643B1 · 2022 [cited by applicant]
EP 3846644B1 · 2022 [cited by applicant]
EP 3860376B1 · 2023 [cited by applicant]
GB 1484573A · 1977 [cited by applicant]
KR 1020160004298A · 2016 [cited by applicant]
KR 1020190083314A · 2019 [cited by applicant]
WO WO9312675A2 · 1993 [cited by applicant]
WO WO9520330A1 · 1995 [cited by applicant]
WO WO9530411A1 · 1995 [cited by applicant]
WO WO2005007068A1 · 2005 [cited by applicant]
WO WO2012026963A2 · 2012 [cited by applicant]
WO WO2012134380A1 · 2012 [cited by applicant]
WO WO2013030202A1 · 2013 [cited by applicant]
WO WO2015179388A1 · 2015 [cited by applicant]
WO WO2015193242A2 · 2015 [cited by applicant]
WO WO2015197674A1 · 2015 [cited by applicant]
WO WO2017046363A1 · 2017 [cited by applicant]
WO WO2017075975A1 · 2017 [cited by applicant]
WO WO2018122375A1 · 2018 [cited by applicant]
WO WO2018224339A1 · 2018 [cited by applicant]
WO WO2019015339A1 · 2019 [cited by applicant]
WO WO2019048880A1 · 2019 [cited by applicant]
WO WO2019071910A1 · 2019 [cited by applicant]
WO WO2019086859A1 · 2019 [cited by applicant]
WO WO2019129843A1 · 2019 [cited by applicant]
WO WO2019193209A1 · 2019 [cited by applicant]
WO WO2019193311A1 · 2019 [cited by applicant]
WO WO2020025718A1 · 2020 [cited by applicant]
WO WO2021026443A1 · 2021 [cited by applicant]
Tomas, et al., (May 26, 2017) “Laponite®: A Key Nanoplatform for Biomedical Applications?” Nanomedicine: Nanotechnology, Biology and Medicine, 14(7):2407-2420. [cited by applicant]
Chan, et al. (May 2009), Prediction Models for Shape and Size of ca-Alginate Macrobeads Produced Through Extrusion-Dripping Method, Journal of Colloid and Interface Science 338(1):63-72. [cited by applicant]